Clinical Trial

ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Primary completion moved earlier: 2028-09-11 -> 2026-10-14 2026-08-11
minor Completion moved earlier: 2028-11-07 -> 2026-10-14 2026-08-11
Trial Details
NCT Number NCT07473973
Lead Sponsor Inozyme Pharma
Collaborators: BioMarin Pharmaceutical
Conditions Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy 1
Enrollment 12 participants
Start Date 2025-03-26
Primary Completion 2026-10-14 (estimated)
Study Completion 2026-10-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-10